The multikinase inhibitor sorafenib targets SCD1 through the ATP-AMPK-mTOR-SREBP1 pathway to suppress MUFA synthesis, disrupt lipogenesis, induce liver cancer cell death, and enhance sensitivity to sorafenib (89, 90) Docetaxel effectively impedes the tumor progress in PRAD by down-regulating mRNA and protein levels of SREBP1 and SCD1. The gene discussed is SREBF1; the disease is prostate adenocarcinoma.